NCT02820883View on ClinicalTrials.gov

A Study of a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

August 31, 2016

Study Completion Date

August 31, 2016

Conditions
Staphylococcus Aureus Infection
Interventions
BIOLOGICAL

Staphylococcus aureus vaccine (60µg/per protein)

two doses of 60µg/0.6ml per dose

BIOLOGICAL

Staphylococcus aureus vaccine (30µg/per protein)

two doses of 30µg/0.6ml per dose

BIOLOGICAL

Staphylococcus aureus vaccine (15µg/per protein)

two doses of 15µg/0.6ml per dose

Trial Locations (1)

225452

Taixing county disease control and prevention, Taishing

Sponsors
All Listed Sponsors
collaborator

Chengdu Olymvax Biopharmaceuticals Inc.

INDUSTRY

collaborator

Third Military Medical University

OTHER

lead

Jiangsu Province Centers for Disease Control and Prevention

NETWORK

NCT02820883 - A Study of a Recombinant Staphylococcus Aureus Vaccine (Escherichia Coli) in Healthy Adults | Biotech Hunter | Biotech Hunter